Cargando…

AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice

Diabetic nephropathy (DN) is a major cause of end-stage kidney disease, where TGF-β1/Smad signaling plays an important role in the disease progression. Our previous studies demonstrated a combination of Traditional Chinese Medicine derived Smad7 agonist Asiatic Acid (AA) and Smad3 inhibitor Naringen...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jeff Yat-Fai, Tang, Patrick Ming-Kuen, Chan, Max Kam-Kwan, Wang, Li, Huang, Xiao-Ru, To, Ka-Fai, Ma, Ronald CW, Lan, Hui-Yao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461652/
https://www.ncbi.nlm.nih.gov/pubmed/36147472
http://dx.doi.org/10.7150/ijbs.72977
_version_ 1784787003348353024
author Chung, Jeff Yat-Fai
Tang, Patrick Ming-Kuen
Chan, Max Kam-Kwan
Wang, Li
Huang, Xiao-Ru
To, Ka-Fai
Ma, Ronald CW
Lan, Hui-Yao
author_facet Chung, Jeff Yat-Fai
Tang, Patrick Ming-Kuen
Chan, Max Kam-Kwan
Wang, Li
Huang, Xiao-Ru
To, Ka-Fai
Ma, Ronald CW
Lan, Hui-Yao
author_sort Chung, Jeff Yat-Fai
collection PubMed
description Diabetic nephropathy (DN) is a major cause of end-stage kidney disease, where TGF-β1/Smad signaling plays an important role in the disease progression. Our previous studies demonstrated a combination of Traditional Chinese Medicine derived Smad7 agonist Asiatic Acid (AA) and Smad3 inhibitor Naringenin (NG), AANG, effectively suppressed the progression of renal fibrosis in vivo. However, its implication in type-2 diabetic nephropathy (T2DN) is still unexplored. Here, we detected progressive activation of Smad3 but reduction of Smad7 in db/db mice during T2DN development. Therefore, we optimized the dosage and the combination ratio of AANG to achieve a better rebalancing Smad3/Smad7 signaling for treatment of T2DN. Unexpectedly, preventive treatment with combined AANG from week 4 before the development of diabetes and T2DN effectively protected against the onset of T2DN. In contract, these inhibitory effects were lost when db/db mice received the late AANG treatment from 12-24 weeks. Surprisingly, preventive treatment with AANG ameliorated not only T2DN but also the primary disease type-2 diabetes (T2D) with relative normal levels of fasting blood glucose and HbA1c, and largely improving metabolic abnormalities especially on insulin insensitivity and glucose tolerance in db/db mice. Mechanistically, AANG effectively prevented both Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation in the diabetic kidney in vivo and advanced glycation end-products (AGE) stimulated tubular epithelial mTEC cells in vitro. More importantly, we uncovered that preventive treatment with AANG effectively protected against diabetic-associated islet injury via restoring the β cell development in db/db mice. Taken together, we discovered that the early treatment with combined AANG can effectively protect against the development of T2D and T2DN via mechanism associated with protection against Smad3-depenedent islet injury.
format Online
Article
Text
id pubmed-9461652
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-94616522022-09-21 AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice Chung, Jeff Yat-Fai Tang, Patrick Ming-Kuen Chan, Max Kam-Kwan Wang, Li Huang, Xiao-Ru To, Ka-Fai Ma, Ronald CW Lan, Hui-Yao Int J Biol Sci Research Paper Diabetic nephropathy (DN) is a major cause of end-stage kidney disease, where TGF-β1/Smad signaling plays an important role in the disease progression. Our previous studies demonstrated a combination of Traditional Chinese Medicine derived Smad7 agonist Asiatic Acid (AA) and Smad3 inhibitor Naringenin (NG), AANG, effectively suppressed the progression of renal fibrosis in vivo. However, its implication in type-2 diabetic nephropathy (T2DN) is still unexplored. Here, we detected progressive activation of Smad3 but reduction of Smad7 in db/db mice during T2DN development. Therefore, we optimized the dosage and the combination ratio of AANG to achieve a better rebalancing Smad3/Smad7 signaling for treatment of T2DN. Unexpectedly, preventive treatment with combined AANG from week 4 before the development of diabetes and T2DN effectively protected against the onset of T2DN. In contract, these inhibitory effects were lost when db/db mice received the late AANG treatment from 12-24 weeks. Surprisingly, preventive treatment with AANG ameliorated not only T2DN but also the primary disease type-2 diabetes (T2D) with relative normal levels of fasting blood glucose and HbA1c, and largely improving metabolic abnormalities especially on insulin insensitivity and glucose tolerance in db/db mice. Mechanistically, AANG effectively prevented both Smad3-mediated renal fibrosis and NF-κB-driven renal inflammation in the diabetic kidney in vivo and advanced glycation end-products (AGE) stimulated tubular epithelial mTEC cells in vitro. More importantly, we uncovered that preventive treatment with AANG effectively protected against diabetic-associated islet injury via restoring the β cell development in db/db mice. Taken together, we discovered that the early treatment with combined AANG can effectively protect against the development of T2D and T2DN via mechanism associated with protection against Smad3-depenedent islet injury. Ivyspring International Publisher 2022-08-29 /pmc/articles/PMC9461652/ /pubmed/36147472 http://dx.doi.org/10.7150/ijbs.72977 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Chung, Jeff Yat-Fai
Tang, Patrick Ming-Kuen
Chan, Max Kam-Kwan
Wang, Li
Huang, Xiao-Ru
To, Ka-Fai
Ma, Ronald CW
Lan, Hui-Yao
AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice
title AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice
title_full AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice
title_fullStr AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice
title_full_unstemmed AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice
title_short AANG Prevents Smad3-dependent Diabetic Nephropathy by Restoring Pancreatic β-Cell Development in db/db Mice
title_sort aang prevents smad3-dependent diabetic nephropathy by restoring pancreatic β-cell development in db/db mice
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9461652/
https://www.ncbi.nlm.nih.gov/pubmed/36147472
http://dx.doi.org/10.7150/ijbs.72977
work_keys_str_mv AT chungjeffyatfai aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT tangpatrickmingkuen aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT chanmaxkamkwan aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT wangli aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT huangxiaoru aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT tokafai aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT maronaldcw aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice
AT lanhuiyao aangpreventssmad3dependentdiabeticnephropathybyrestoringpancreaticbcelldevelopmentindbdbmice